CXCL9 and cancer: Of note, inhibition of CXCL9/10 production by epigenetic silencing or soluble inhibitors, has been shown to facilitate tumor development in cancer models and patients [19, 35], supporting the importance of CXCL9/10 paracrine effect on immune cell recruitment.